Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 7/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.57 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971767 | 0.84 | HTR2A (0.56) | BCHEFTOPCSK9HTR1AMTNR1A | |
| SCHEMBL1969123 | 0.81 | MTNR1A (0.63) | SLC6A4BCHEFTOHTR1AMTNR1A | |
| SCHEMBL29206522 | 0.80 | MPO (0.61) | MPOSLC6A4GPR84RIPK1PCSK9 | |
| SCHEMBL30877812 | 0.80 | MPO (0.61) | MPOSLC6A4GPR84RIPK1PCSK9 | |
| SCHEMBL1973753 | 0.79 | HTR2A (0.57) | GPR84BCHEALKBH5FTOHTR1A | |
| SCHEMBL1968351 | 0.78 | BCHE (0.67) | SLC6A4BCHEHTR1AMTNR1AHTR2A | |
| SCHEMBL1120483 | 0.77 | GPR84 (0.68) | MPOSLC6A4GPR84RIPK1PCSK9 | |
| SCHEMBL29206457 | 0.77 | MPO (0.58) | MPOSLC6A4GPR84ALKBH5FTO | |
| SCHEMBL2402869 | 0.76 | GPR84 (0.51) | MPOSLC6A4GPR84BCHEHTR1A | |
| SCHEMBL1966782 | 0.75 | MPO (0.57) | MPOSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | MPO 3915/4885SLC6A4 781/4885GPR84 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.